The pace of vaccine development for this virus is dizzyingly rapid – 7 or 8 times as fast as that for SARS and MERS, and 30 to 200+ times as fast as for other disease outbreaks over the last century.

Click on the thumbnail at left for a graphical look at this impressive development effort (then hit the Back button to return here).

Here are resources that are keeping track of some of the leading contenders in the race to get humans a vaccine that might let us coexist with SARS-CoV-2.

STAT News – STAT is an authoritative source for medical news. Their list, implemented in a Google Doc, is graph­ically unadorned but rich in detail. It lists a selection of (at time of publication) 19 vaccines in stages from pre-clinical to Phase II trials. The spreadsheet claims it is updated every 5 minutes, but that may be just Google’s cloud updating, not the content of the list itself.

Regulatory Affairs Professionals Society – RAPS provides a list of 36 vaccine candidates grouped by devel­op­mental stage. For each there is a section on study design and details, which can optionally be displayed. Of the resources listed here, this tool provides by far the most down-and-dirty detail on each candidate vaccine. The RAPS list will be updated weekly.

NY Times – The Times’s list is graphically more ap­peal­ing, with company logos and color-coded devel­op­ment stages. It groups the candidate vaccines by the technology on which they are based, and lists 26 of them at present, from Phase I to Phase III (many of the latter in China). It appears that this list is updated from time to time.

The mother lode – The Milkin Institute maintains this Google Doc listing (at this writing) 140 vaccines in development, plus a section for treatments. (I have linked to this resource before.) The candidate vaccines range from the pre-clinical stage through Phase III. The way they have arranged the Google Doc’s UI makes it awkward to browse: only four candidate vaccines are (partially) in view at any one time. You can download the spreadsheet in Excel format, and I recommend you do that if you want to peruse it at leisure.

My go-to source for insight into the science, Derek Lowe, has promised an updated roundup soon of the vaccine development scene; I will update this post with any insights gleaned after it goes live.

---

[ Note added 2020-06-30: ] Here is Lowe’s promised roundup. He profiles where the development stands on the 31 candidate vaccines that are farthest along in the process, broken down as follows:

9     viral vectors (including Oxford)
8     genetic vaccines (including Moderna)
6     recombinant protein vaccines
2     attenuated virus vaccines
6     inactivated virus vaccines (including SinoVac)

His take is based on an up-to-the-minute reading of the scientific literature — he puts little stock in press releases, though well aware of them